This review intends to provide the reader with a clear and concise overview of how preparative continuous flow organic chemistry could potentially impact on current important societal challenges. These societal challenges include health/well‐being and sustainable development. Continuous flow chemistry has enabled significant advances for the manufacturing of pharmaceuticals, as well as for biomass valorization toward a biosourced chemical industry. Examples related to pharmaceutical production are herein focused on (a) the implementation of flow chemistry to reduce the occurrence of drug shortages, (b) continuous flow manufacturing of orphan drugs, (c) continuous flow preparation of active pharmaceuticals listed on the WHO list of essential medicines and (d) perspectives for the manufacturing of peptide‐based pharmaceuticals. Examples related to sustainable development are focused on the valorization of biosourced platform molecules. Besides positive impacts on societal challenges, this review also illustrates some of the potentially most threatening perspectives of continuous flow technology within the actual context of terrorism and drug abuse.

Continuous flow preparation of antidepressant ketamine and analogs under sustainable conditions.

The unique reactivity profile of -chloronitroso derivatives is expressed to its fullest potential through the development of an integrated, modular and scalable continuous flow process for the electrophilic α-aminohydroxylation of...

Herein is reported the development of a continuous flow generator that produces highly reactive organic hypochlorites for the chemical neutralization of sulfur-based chemical warfare agent (CWA) simulants. The generator relies...

No abstract

The Cover Feature shows some areas of high societal impact for preparative continuous flow organic synthesis. Continuous flow chemistry has profoundly changed the manufacture of chemicals. Examples are herein focused on a) active pharmaceuticals currently in shortage, b) orphan drugs, c) WHO essential medicines, d) peptide‐based pharmaceuticals and e) biobased platform molecules. Perspectives within the context of terrorism and drug abuse are also discussed. More information can be found in the https://doi.org/10.1002/ejoc.201800149